Ma'n Zawati, Université Laval

Research

Collagen Epidermolysis Bullosa Gene Therapy Novel Treatment Pediatric Disease Rare Disease Skin Genetic Disease Skin Grafting

Latest funding

GMEB-SASS: The first clinical trial phase I/II using a genetically modified epidermolysis bullosa self-assembled skin substitute to treat dystrophic epidermolysis bullosa, a severe rare skin disease
CIHR · 2024 · Principal investigator
$1,137,500

All 1 grants and awards

GMEB-SASS: The first clinical trial phase I/II using a genetically modified epidermolysis bullosa self-assembled skin substitute to treat dystrophic epidermolysis bullosa, a severe rare skin disease

Principal investigatorCIHR2024Operating Grant:Bringing Rare Disease Gene Therapies to Clinical Trial Readiness

Principal investigators: Germain, Lucie; Pope, Elena; Caruso, Manuel P; Fradette, Julie; Guertin, Jason R; Laprise, Catherine; Laurin, Mélanie; Zawati, Ma'n Hilmi M.

Keywords: Collagen; Epidermolysis Bullosa; Gene Therapy; Novel Treatment; Pediatric Disease; Rare Disease; Skin Genetic Disease; Skin Grafting; Stem Cells, Skin; Tissue Engineering

$1,137,500

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Mention their CIHR grant from 2024

Subject: Prospective PhD student: Collagen Dear Professor Zawati, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. Your research on collagen connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "GMEB-SASS: The first clinical trial phase I/II using a genetically modified epidermolysis bullosa self-assembled skin substitute to treat dystrophic epidermolysis bullosa, a severe rare skin disease" (2024), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]